BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Insulin receptor substrate 1 (IRS1); K-Ras (KRAS); Janus kinase-1 (JAK-1); JAK-2

July 28, 2016 7:00 AM UTC

Patient sample, cell culture and mouse studies suggest JAK inhibitors could help treat KRAS-mutant lung cancers. In patients with KRAS-mutant lung adenocarcinoma, low primary tumor levels of IRS1 were associated with poor survival. In an IRS1-knockout mouse model of KRAS-mutant lung cancer, a JAK1 inhibitor tool compound or the JAK-1/JAK-2 inhibitor AZD1480 decreased inflammation and tumor burden compared with no treatment. Next steps could include testing JAK inhibitors in models of other KRAS-mutant lung cancers...